Gazyva Succeeds In NOBILITY Lupus Nephritis Study But What Next?
Executive Summary
Genentech refrained from committing to further development of its CD20 inhibitor in the indication despite meeting endpoints in Phase II study.
You may also be interested in...
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Roche’s Pipeline Prospects Promise Steady Sailing To More Growth
Analysts increasingly see Roche’s pipeline and newly launched drugs winning over investors and neutralizing worries over biosimilars and potential US pricing reforms. Its 16 September pipeline update in London may reinforce that.
Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.